Study of A-301 in patients with patchy alopecia areata

Trial Profile

Study of A-301 in patients with patchy alopecia areata

Planning
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs ATI 50002 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions
  • Sponsors Aclaris Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to an Aclaris Therapeutics media release, the company has submitted an IND Application to the U.S. FDA. Following FDA clearance of the IND, the company expects to initiate this trial in the second half of 2017.
    • 29 Mar 2016 New trial record
    • 23 Mar 2016 According to Aclaris Therapeutics media release, company plans to submit IND in in the first half of 2017 and plans to commence this study in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top